secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kezar Life Sciences, Inc. (KZR)
CIK:        0001645666
Form:       8-K
Filed at:   2026-05-11T13:30:08+00:00
Accession:  0001140361-26-020407
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kezar Life Sciences acquired by Aurinia for $6.955/sh + CVR; stock to be delisted
--------------------------------------------------------------------------------

- Tender offer expired May 8, 2026; 5,927,580 shares (80.2% of outstanding) validly tendered.
- Merger completed May 11, 2026 under DGCL Section 251(h); Kezar became wholly owned subsidiary of Aurinia.
- Consideration: $6.955 per share in cash plus one contingent value right per share (CVR Agreement filed as Exhibit 10.1).
- Entire board (7 directors) resigned; Kevin Tang and others from Merger Sub became directors and officers of surviving corporation.
- Shares will be suspended and delisted from Nasdaq; company intends to file Form 15 to terminate registration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645666/000114036126020407/0001140361-26-020407-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645666/000114036126020407/ef20072746_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-020407

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer